Topical Composition for Musculoskeletal Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for musculoskeletal pain, such as those from arthritis and soft tissue trauma, often rely on anti-inflammatory drugs like NSAIDs, which are not always effective for many individuals.
Innovation Solution
A topical composition combining neuropathic analgesics, muscle relaxants, anesthetics, and anti-inflammatory analgesics, specifically Amitriptyline, Baclofen, Lidocaine, and Ketoprofen, formulated with an oil phase and poloxamer gel phase, is developed to provide direct pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory drugs like NSAIDs are used to treat musculoskeletal pain, then pain relief is provided, but effectiveness is insufficient for many individuals
Solution Approach 1:
The patent combines multiple active ingredients with different mechanisms of action (neuropathic analgesic, muscle relaxant, anesthetic, and anti-inflammatory analgesic) into a single topical composition. This combination approach allows the formulation to address different pain mechanisms simultaneously, improving overall effectiveness and adaptability across different patient populations compared to single-agent NSAID therapy.
2Reliability
If oral anti-inflammatory medications are used, then pain relief is achieved, but side effects increase and oral medication use must be reduced
Solution Approach 1:
The patent employs a topical delivery system as an intermediary between the active ingredients and the pain site. This localized delivery mechanism allows the medications to act directly at the pain source through the skin, reducing systemic absorption and associated side effects while maintaining effective pain relief, thereby enabling reduced oral medication use.
3Reliability
If a multi-component topical composition is developed, then pain relief effectiveness is improved, but formulation complexity increases
Solution Approach 1:
The patent specifies precise concentration ranges for each active ingredient (neuropathic analgesic: 0.5-10%, muscle relaxant: 0.5-10%, anesthetic: 0.5-10%, anti-inflammatory analgesic: 0.5-20%) to optimize the balance between effectiveness and formulation manageability. These parameter optimizations allow the complex multi-component formulation to be controlled and standardized during manufacturing while maintaining therapeutic efficacy.
Data Source
AI summary
The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.